In many cases, identifying molecular alterations in haematological-oncological diseases is essential in order to confirm the diagnosis, establish a prognosis, help to select a treatment for each patient, and monitor the disease.
NIMGenetics offers conventional tests, such as karyotyping, as well as more advanced technologies, such as array CGH and NGS panels to test for these diseases.
Genomic platform designed by NIMGenetics to identify biomarkers in chronic lymphocytic leukaemia (CLL), combining array CGH and SNP technologies.
This test is performed on peripheral blood or tumour samples, depending on the indication.
Turnaround time: 20 working days from receipt of the sample.
Please remember to attach the Application Form and Informed Consent Form to the sample, which you will find on the right.
Molecular biology allows us to determine the presence of and/or quantify fusion proteins secondary to chromosomal rearrangements/translocations and identify mutations in various genes involved in haematological malignancies.
Conventional and molecular cytogenetics are currently the first-choice techniques for the genetic testing of various haematological diseases. The results of these tests are essential in order to classify these conditions correctly. Their value as a prognostic biomarker has been demonstrated in various haematological diseases, such as acute leukaemia, myelodysplastic syndromes, chronic lymphocytic leukaemia and multiple myeloma, among others.